PCRX
Pacira Biosciences Inc - Estimates $2.4-$2.8 Mln Pre-Tax Charges for Termination - SEC Filing
时间:2025-07-10 19:36:34 市场: 美股 综合
Pacira Biosciences Inc - on July 3 Enters Credit Agreement With Wells Fargo - SEC Filing
时间:2025-07-07 20:01:51 市场: 美股 综合
Pacira Biosciences Inc : RBC Asssumes Coverage With Sector Perform Rating; Target Price $26
时间:2025-07-07 12:44:31 市场: 美股 综合
Pacira Biosciences Inc : Truist Securities Raises Target Price to $25 From $8
时间:2025-01-30 20:33:35 市场: 美股 综合
Pacira Biosciences: Sees Double-Digit Compounded Annual Growth Rate in Product Revenue by 2030
时间:2025-01-10 21:01:39 市场: 美股 综合
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
时间:2024-12-06 21:00:00 市场: 美股 综合
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee
时间:2024-11-14 23:05:00 市场: 美股 综合
Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported
时间:2024-11-14 23:05:00 市场: 美股 综合
Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201
时间:2024-11-14 23:05:00 市场: 美股 综合
Pacira Biosciences Appoints Shawn Cross as Chief Financial Officer
时间:2024-10-21 20:00:00 市场: 美股 综合